

# Intellectual Property Prospector

IP Assets Held by Firms In Transition

May 7, 2007  
Volume 2, Number 19  
Prospector Profiles in this Issue

Company Name	Reference Number	Category Profile
Acro, Inc.	<a href="#">07.0649</a>	Loss/Deficit
Ambient Corporation	<a href="#">07.0650</a>	Audit Concerns
Aveta, Inc.	<a href="#">07.0651</a>	Low Rating
Bion Environmental Technologies, Inc.	<a href="#">07.0652</a>	Loss/Deficit
Central Parking Corporation	<a href="#">07.0653</a>	Low Rating
Cereplast, Inc.	<a href="#">07.0654</a>	Loss/Deficit
Challenger Powerboats, Inc.	<a href="#">07.0655</a>	Audit Concerns
China World Trade Corporation	<a href="#">07.0656</a>	Audit Concerns
Cleveland Biolabs, Inc.	<a href="#">07.0657</a>	Loss/Deficit
Communications Research, Inc.	<a href="#">07.0658</a>	Audit Concerns
Conspiracy Entertainment Corporation	<a href="#">07.0659</a>	Audit Concerns
Elephant Talk Communications, Inc.	<a href="#">07.0660</a>	Audit Concerns
Favrille, Inc.	<a href="#">07.0661</a>	Loss/Deficit
GameZnFlix, Inc.	<a href="#">07.0662</a>	Loss/Deficit
Geovax Labs, Inc.	<a href="#">07.0663</a>	Audit Concerns
Glassmaster Company, Inc.	<a href="#">07.0664</a>	Bankruptcy
Guardian Technologies International, Inc.	<a href="#">07.0665</a>	Audit Concerns
INFe-Human Resources, Inc.	<a href="#">07.0666</a>	Loss/Deficit
Integrated Management Information, Inc.	<a href="#">07.0667</a>	Audit Concerns
Interactive Motorsports and Entertainment Corp.	<a href="#">07.0668</a>	Loss/Deficit
Inverness Medical Innovations, Inc.	<a href="#">07.0669</a>	Low Rating
Lattice, Inc.	<a href="#">07.0670</a>	Audit Concerns
Lixte Biotechnology Holdings, Inc.	<a href="#">07.0671</a>	Audit Concerns
Lpath, Inc.	<a href="#">07.0672</a>	Audit Concerns
Marshall Holdings International, Inc.	<a href="#">07.0673</a>	Audit Concerns
Migo Software Corporation	<a href="#">07.0674</a>	Loss/Deficit
Mobile Area Networks, Inc.	<a href="#">07.0675</a>	Audit Concerns
O2Diesel Corporation	<a href="#">07.0676</a>	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

Company Name	Reference Number	Category Profile
Protosource Corporation	<a href="#">07.0677</a>	Audit Concerns
Regen Biologics, Inc.	<a href="#">07.0678</a>	Audit Concerns
Response Biomedical Corporation	<a href="#">07.0679</a>	Audit Concerns
Security with Advanced Technology, Inc.	<a href="#">07.0680</a>	Audit Concerns
SinoFresh Healthcare, Inc.	<a href="#">07.0681</a>	Audit Concerns
Solomon Technologies, Inc.	<a href="#">07.0682</a>	Loss/Deficit
Sontra Medical Corporation	<a href="#">07.0683</a>	Audit Concerns
Spatializer Audio Laboratories, Inc.	<a href="#">07.0684</a>	Audit Concerns
Spectrascience, Inc.	<a href="#">07.0685</a>	Audit Concerns
Surflect Holdings, Inc.	<a href="#">07.0686</a>	Audit Concerns
Targeted Genetics Corporation	<a href="#">07.0687</a>	Audit Concerns
Teeka Tan Products, Inc.	<a href="#">07.0688</a>	Audit Concerns
Telanetix, Inc.	<a href="#">07.0689</a>	Audit Concerns
TorreyPines Therapeutics, Inc.	<a href="#">07.0690</a>	Loss/Deficit
Tribeworks, Inc.	<a href="#">07.0691</a>	Audit Concerns
Visiphor Corporation	<a href="#">07.0692</a>	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

**Intellectual Property Prospector** identifies companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (<http://BeardGroup.com>). For subscription information call Customer Service at 240-629-3300, ext. 27.

### **Prospector Profile Selection Criteria:**

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.
- Chapter 11, 7, or 15 bankruptcy filing
- Section 363 Sales

**DISCLAIMER:** The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

**ACCURACY & COVERAGE:** The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

**SUBSCRIPTIONS:** Subscription rate: \$575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

**Intellectual Property Prospector** is a publication of **Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, <http://www.beardgroup.com>. ISSN 1935-3901. Copyright 2007. All rights reserved. Publisher: Christopher Beard.

**Prospector  
Profile  
07.0649**

**Acro, Inc.**

37 Inbar St.  
Caesarea, Israel 30889  
+972-4-636-0297

NAICS	334519
Description	Detectors Mfg.
Revenue (mil)	\$0.00
Income (mil)	(\$1.35)
Assets (mil)	\$0.58
Liability (mil)	\$0.15
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Acro, Inc. reported a net loss of \$1,351,583 for the year ended December 31, 2006, almost nine times higher than the net loss reported last year of \$157,665. The 2006 net loss includes \$749,340 in stock-based compensation to non-employees. The Company has an accumulated deficit of \$1,552,415 as of December 31, 2006. The Company also used cash for operating activities of \$596,506 during 2006, almost 10 times higher than the cash used for operating activities of \$61,501 last year.

**Intellectual Property:** On March 15, 2006, the Company completed the acquisition of a patent pursuant to a patent purchase agreement with Dr. Ehud Keinan. The patent, U.S. Patent No. 6,767,717, describes an invention that provides a method of detection of peroxide based explosives. Dr. Ehud Keinan has also agreed to provide consulting services in order to develop the patent into a commercially viable product. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company develops a product for the detection of peroxide-based explosives for the homeland security market.

**Officers:** Gadi Aner (Interim CEO)

**Auditor:** KPMG International

**Securities:** Common Stock-Symbol ACRI.OB; OTC BB;  
67,131,686 common shares outstanding as of March 23, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0650**

**Ambient Corporation**

79 Chapel Street  
Newton, MA 02458  
(617) 332-0004

NAICS	334200
Description	Communications Equipment Mfg.
Employees	34
Revenue (mil)	\$2.34
Income (mil)	(\$12.74)
Assets (mil)	\$5.43
Liability (mil)	\$2.63
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Rotenberg Meril Solomon Bertiger & Guttilla PC raised substantial doubt about Ambient Corporation's ability to continue as a going concern due to its recurring losses and negative cash flows from operations.

**Intellectual Property:** The Company believes that its success depends on the continued development and protection of proprietary technologies. In addition to enabling them to take a leading position in the broadband over power lines (BPL) marketplace, a large intellectual property base opens up revenue generating licensing possibilities. It continues to develop the coupling technology critical to BPL, and the Company has introduced next generation couplers for medium voltage overhead and underground and low voltage applications. As of January 2007, the Company holds 15 patents, with more than 183 independent claims allowed, on this critical inductive coupling technology and its applications. It has several other patent applications either allowed, pending, or under review and has also applied for corresponding patents in key markets worldwide. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company engages in the design, development, commercialization, and marketing of broadband over power lines (BPL) equipment, technologies, and services in North America.

**Officers:** John Joyce (CEO & Dir.); Michael Widland (Dir.); D. Thomas Pierce (Dir.); Michael Thomas Higgins (Dir.)

**Auditor:** Rotenberg Meril Solomon Bertiger & Guttilla PC

**Securities:** Common Stock-Symbol ABTG.OB; OTC BB;  
220,966,402 common shares outstanding as of March 27, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0651**

**Aveta, Inc.**

173 Bridge Plaza North  
Fort Lee, NJ 07024  
(201) 969-2300

NAICS		621491
Description		Medical Centers
Employees		1,304
Revenue	(mil)	\$736.61
Income	(mil)	\$4.19
Assets	(mil)	\$498.77
Liability	(mil)	\$460.55
(for the year ended 12/31/2005)		

**Category:** Low Rating

**Event:** Standard & Poor's Ratings Services lowered its counterparty credit ratings on Aveta, Inc. and its subsidiaries to 'CCC' from 'B-'. The rating agency removed the ratings from CreditWatch with negative implications. Credit analyst Joseph Marinucci said that the downgrade reflects the deterioration of the Company's financial condition and business profile due to the adverse development in its core operations in Puerto Rico. The negative outlook reflects the potential for sustained business and financial profile challenges for the remainder of 2007, which could further pressure the Company's credit profile.

**Intellectual Property:** The Company's health plan in Puerto Rico has operated under the common law tradename Medicare y Mucho Más since inception. In addition, the names "Aveta" and "North American Medical Management" are its federally registered service marks. In addition, the Company uses the common law tradenames PrimeCare Medical Network, PMNI and NAMM. [SEC Filing 10-KSB 04-11-06]

**Description:** The Company, formerly known as Aveta Holdings LLC and Green Field II LLC, provides managed health care services to Medicare beneficiaries in the U.S.

**Officers:** Daniel E. Straus (Chair); Timothy J. O'Donnell (Pres., CEO & Dir.); John S. Brittain, Jr. (EVP & CFO); Jess Parks (EVP & COO); Eugene Huang (SVP); Howard P. Kamins (VP, Gen. Counsel & Sec.); Douglas R. Malton (VP); Lawrence M. Dunn (VP & Controller); Keith Brauer (VP); John D. Mark (Dir.); Stuart H. Altman (Dir.); Jonathan Kolatch (Dir.); David Roberts (Dir.); Alan D. Solomont (Dir.)

**Auditor:** KPMG LLP

**Securities:** 28,750,000 common shares outstanding as of June 2, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0652**

**Bion Environmental Technologies, Inc.**

641 Lexington Avenue, 17th Floor  
New York, NY 10022  
(212) 758-6622

NAICS	562000
Description	Waste Mgt. Services
Employees	10
Revenue (mil)	\$0.00
Income (mil)	(\$5.17)
Assets (mil)	\$1.27
Liability (mil)	\$4.55
(for the year ended 6/30/2006)	

**Category:** Loss/Deficit

**Event:** Bion Environmental Technologies Inc.'s balance sheet at March 31, 2007, showed \$1,122,237 in total assets and \$5,274,112 in total liabilities, resulting in a \$4,151,875 total stockholders' deficit. The Company also showed strained liquidity with \$870,761 in total current assets available to pay \$1,452,371 in total current liabilities.

**Intellectual Property:** The Company owns eight United States patents, one Canadian patent and one New Zealand patent. The Company has two patent applications pending for "Low Oxygen Biologically Mediated Nutrient Removal" and "Environmentally Compatible Integrated Food and Energy Production System". The Company believes that a strong patent position is increasingly important to compete effectively in the businesses on which it is focused. It is likely that the Company will file applications for additional patents in the future. It also may become necessary or desirable in the future to obtain patent and technology licenses from other companies relating to technologies that may be employed in future products or processes. The Company generally requires all employees and consultants, including management, to sign a non-disclosure and invention assignment agreement upon employment. [SEC Filing 10-SB12G/A 02-01-07]

**Description:** The Company, through its subsidiaries, engages in the development and testing of a second generation of its Nutrient Management Systems technology to provide waste management solutions to the agricultural industry.

**Officers:** Mark A. Smith (Pres., Interim CFO, Gen. Counsel & Dir.); Jon Northrop (Corp. Sec. & Dir.); George W. Bloom (COO); James W. Morris (CTO); Jeff Kapell (VP); David Mager (VP); Jere Northrop (Dir.)

**Auditor:** HP Horwath, P.C.

**Securities:** Common Stock-Symbol BNET.PK; Other OTC; 8,064,105 common shares outstanding as of April 19, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0653**

**Central Parking Corporation**

2401 21st Avenue South, Suite 200  
Nashville, TN 37212  
(615) 297-4255

NAICS		812930
Description		Parking Lots
Employees		18,940
Revenue	(mil)	\$1,109.44
Income	(mil)	\$27.86
Assets	(mil)	\$788.37
Liability	(mil)	\$381.85
(for the year ended 9/30/2006)		

**Category:** Low Rating

**Event:** Standard & Poor's Ratings Services assigned a 'CCC+/RR5' rating on Central Parking Corp.'s \$50 million second-lien facility and lowered the Company's convertible trust issued preferred securities to 'CCC' from 'CCC+'. The rating outlook is negative. Credit analyst Mark Salierno said that the downgrade reflects the Company's more aggressive financial policy and more highly leveraged capital structure.

**Intellectual Property:** The Company has registered the names CPC, Central Parking System and Central Parking Corporation, and its logo with the U.S. Patent and Trademark Office and has the right to use them throughout the United States except in Chicago and Atlantic City. The Company also owns registered trademarks for Square Industries, Kinney System, Allied Parking and Allright Parking and operates various parking locations under those names. The Company uses the name "Chicago Parking System" in Chicago and "CPS Parking" in Seattle and Milwaukee. The Company has registered the name "Control Plus" and its symbol in London and has registered that name and symbol in association with its on-street parking activities in Richmond, Virginia. [SEC Filing 10-K 12-14-06]

**Description:** The Company provides parking and related services in the U.S., Canada, and the United Kingdom. The Company owns, leases, and manages multilevel parking facilities and surface lots.

**Officers:** Monrow J. Carell, Jr. (Chair); Emanuel Eads (Pres. & CEO); Jeff Heavrin (SVP & CFO); Claude Blankenship (Dir.); Lewis Katz (Dir.); Edward G. Nelson (Dir.); Owen Shell, Jr. (Dir.); William Smith (Dir.); Ray Baker (Dir.); Kathryn Brown (Dir.)

**Auditor:** KPMG LLP

**Securities:** Common Stock Symbol CPC; NYSE;  
32,240,497 common shares outstanding as of February 2, 2007.

[Return to top](#)



**Prospector  
Profile  
07.0654**

**Cereplast, Inc.**

3421-3433 West El Segundo Boulevard  
Hawthorne, CA 90250  
(310) 676-5000

NAICS	325211
Description	Plastics & Resin Mfg.
Employees	22
Revenue (mil)	\$0.84
Income (mil)	(\$3.38)
Assets (mil)	\$2.61
Liability (mil)	\$1.68
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Cereplast, Inc. reported a net loss for the year ended December 31, 2006 of \$3,383,753 on revenues of \$836,729, higher than last year's net loss of \$1,118,906 on revenues of \$545,770. As a result of its recurring losses, the Company has an accumulated deficit of \$4,945,085 and strained liquidity with \$1,361,631 in total current assets available to pay \$1,552,356 in total current liabilities.

**Intellectual Property:** The Company regards copyrights, service marks, trademarks, trade dress, trade secrets and similar intellectual property as critical to its success. The Company has filed for patent and trademark protection for its proprietary technology. In 2006, the Company was granted registration of several new trademarks in different International classes covering packaging and plastic resin, including Cereplast® and Nat-Ur®, which have been granted in the United States and in several countries abroad. Currently, the Company has about 12 mark registrations on file. In 2006, Cereplast was granted patent number 7,138,439 in the U.S. for its proprietary resin formulation. The Company obtained clearance from the World International Patent Office on two patent applications and has entered the national phase for these patents in several countries around the world. In addition, the Company acquired the exclusive rights to two other patents from University of Nebraska relating to thermoplastic starch. The Company has also filed two additional patents applications with the US Patent Office in 2005 and 2006. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company engages in the development and commercialization of bio-based resins in the United States, Europe, and Asia.

**Officers:** Frederic Scheer (Pres., CEO & Dir.); Stephan Garden (SVP); William Kelly (SVP); Michael Muchin (VP); Robert L. Dobbs (VP); Raylan Jensen (Dir.); Brian Altounian (Dir.)

**Auditor:** HJ Associates & Consultants, LLP

**Securities:** Common Stock-Symbol CERP.OB; OTC BB;  
206,683,516 common shares outstanding as of March 15, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0655**

**Challenger Powerboats, Inc.**

300 Westlink Drive  
Washington, MO 63090  
(636) 390-9000

NAICS		336612
Description		Boat Building
Employees		70
Revenue	(mil)	\$0.24
Income	(mil)	(\$9.13)
Assets	(mil)	\$4.65
Liability	(mil)	\$17.97
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Jaspers + Hall, PC raised substantial doubt about Challenger Powerboats, Inc.'s ability to continue as a going concern after auditing the Company's financial statements as of Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's recurring losses from operations and its difficulties in generating sufficient cash flow to meet obligations and sustain operations. For the year ended Dec. 31, 2006, the Company generated total revenue of \$238,171 and incurred a net loss of \$9,133,144. As of Dec. 31, 2006, the Company listed total assets of \$4,653,478 and total liabilities of \$17,968,467, resulting in a total shareholders' deficit of \$13,314,989. The Company also has strained liquidity with total current assets of \$1,991,808 available to pay total current liabilities of \$5,980,531.

**Intellectual Property:** The Company's intellectual property is important to its business. The Company relies on a combination of trade secret laws, confidentiality procedures and contractual provisions to protect intellectual property. The Company licenses patents and patents-pending that relate to the construction and design of the sleek, progressive "V" and double pad-bottomed "V-hull" boat. This Duo-Delta Conic, or DDC hull is designed so that as water hits the hull, it flows to the next convenient degree, creating a lift and literally raising the boat to the top of the water. [SEC Filing 10-KSB 04-16-07]

**Description:** Challenger Powerboats, Inc. designs, manufactures, and sells fast offshore sport boats and family cruisers that target the recreational power boat market.

**Officers:** Michael Novielli (Chair); Laurie Phillips (CEO & CFO); Jack Clark (COO); Theodore Smith (Sec. & Dir.); Barrett Evans (Treas.); Kevin Ryan (Dir.); Douglas Leighton (Dir.)

**Auditor:** Jaspers + Hall, PC

**Securities:** Common Stock-Symbol CPWB.OB; OTC BB; 68,508,579 common shares outstanding as of March 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0656**

**China World Trade Corporation**

3/F Goldlion Digital Network Ctr.  
138 Tiyu Rd. East, Tianhe  
Guangzhou, People's Republic of China  
(001-8620) -2886-0608

NAICS	813910
Description	Business Clubs
Employees	39
Revenue (mil)	\$4.34
Income (mil)	(\$10.09)
Assets (mil)	\$13.53
Liability (mil)	\$2.52
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Child Van Wagoner & Bradshaw PLLC raised doubts on China World Trade Corporation's ability to continue as a going concern after auditing the Company's financial statements as of Dec. 31, 2006. The auditing firm pointed to the Company's losses from operations during the year, despite having a positive working capital. Net loss for fiscal year 2006 was \$10,090,975, resulting in an accumulated deficit of \$28,165,010 as of Dec. 31, 2006.

**Intellectual Property:** On May 7, 2004, the Company acquired 51% of the capital stock of CEO Clubs China Limited. CEO Clubs China has authorized chapters to operate under the "CEO Clubs" trademarks in the Greater China Region, including the PRC, Hong Kong and Taiwan. The Company intends to negotiate and acquire the necessary approval from WTC Association to license the China World Trade Center intellectual property rights including the logo and trademark to third parties. [SEC Filing 10-KSB 04-16-07]

**Description:** The Company operates through 11 direct and indirect, majority and wholly-owned subsidiaries that operate businesses in China and is engaged in business clubs, business travel and other business value-added services.

**Officers:** William Chi Hung Tsang (Chair & Pres.); Zeliang Chen (Vice Chair); John H.W. Hui (Vice Chair); Chi Ming Chan (CEO & Dir.); Man Ha (CFO); Chao Ming Luo (Dir.); Ye Xin Long (Dir.); Hamid R. Seyedin (Dir.)

**Auditor:** Child Van Wagoner & Bradshaw PLLC

**Securities:** Common Stock-Symbol CWTD.OB; OTC BB;  
43,865,923 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0657**

**Cleveland Biolabs, Inc.**

11000 Cedar Avenue, Suite 290  
Cleveland, OH 44106-3052  
(216) 229-2251

NAICS	541710
Description	Biotechnology
Employees	35
Revenue (mil)	\$1.71
Income (mil)	(\$7.22)
Assets (mil)	\$6.42
Liability (mil)	\$0.82
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Cleveland Biolabs, Inc. reported a net loss for the year ended December 31, 2006 of \$7,222,644, higher than the net loss of \$2,386,455 in 2005 and \$2,523,142 in 2004. The Company also reported increased revenues of \$1,708,214 in 2006, compared to \$1,138,831 in 2005 and \$636,341 in 2004. As a result of its recurring losses, the Company reported an accumulated deficit of \$12,775,910 at December 31, 2006. The Company also used cash for operating activities of \$6,653,602 during fiscal year 2006, higher than the \$1,730,513 used in 2005 and \$207,911 in 2004.

**Intellectual Property:** As a result of the license agreement with the Cleveland Clinic Foundation, the Company has filed 13 patent applications covering new classes of anticancer and radiation-protecting compounds, their utility and mode of action. The Company's intellectual property platform is based primarily on these 13 patent applications exclusively licensed by the Cleveland Clinic. The Company also owns three patent applications for Quinacrine Isomers; Modulation of Androgen Receptor for Treatment of Prostate Cancer; and Method of Increasing Hematopoietic Stem Cells. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins in the United States.

**Officers:** Bernard L. Kasten (Chair); Michael Fonstein, Ph.D. (Pres., CEO & Dir.); Yakov Kogan, Ph.D. (EVP & Dir.); Andrei Gudkov, Ph.D. (Chief Scientific Officer & Dir.); John A. Marhofer, Jr., CMA, CFM (CFO); James J. Antal (Dir.); Paul DiCorleto (Dir.); H. Daniel Perez (Dir.)

**Auditor:** Meaden & Moore Ltd.

**Securities:** Common Stock-Symbol CBLI; NasdaqGM;  
11,889,099 common shares outstanding as of March 14, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0658**

**Communications Research, Inc.**

400C Lake Street  
Ramsey, NJ 07446  
(201) 825-9100

NAICS	541710
Description	Engineering R&D
Employees	2
Revenue (mil)	\$0.04
Income (mil)	(\$1.41)
Assets (mil)	\$0.00
Liability (mil)	\$0.19
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Chisholm, Bierwolf & Nilson, LLC expressed substantial doubt about Communications Research, Inc.'s ability to continue as a going concern due to its recurring losses from operations and net capital deficiency.

**Intellectual Property:** The Company has totally phased out their line of PC-based desktop videoconferencing products and Visual Products Division. The proprietary Visual-EZ and Communicator products have been frozen with only the intellectual property, trademarks and copyrights retained if required in the future. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company provides research and development for manufacturers and clients using RF Broadband technology for video and data products.

**Officers:** Carl R. Ceragno (Pres., Treas. & Dir.); Lawrence S. Hartman, Esq. (VP & Dir.); Almajeon O'Connor (Sec.)

**Auditor:** Chisholm, Bierwolf & Nilson, LLC

**Securities:** 159,398,444 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0659**

**Conspiracy Entertainment Corporation**

612 Santa Monica Boulevard  
Santa Monica, CA 90401  
(310) 260-6150

NAICS	511210
Description	Games Publisher
Employees	3
Revenue (mil)	\$0.80
Income (mil)	(\$1.47)
Assets (mil)	\$1.28
Liability (mil)	\$4.46
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Chisholm Bierwolf & Nilson LLC expressed substantial doubt about the ability of Conspiracy Entertainment Holdings, Inc. to continue as a going concern after auditing the Company's financial statements as of Dec. 31, 2006, and 2005. The auditing firm pointed to the Company's recurring operating losses and lack of working capital. For the years ended Dec. 31, 2006, the Company reported total revenues of \$803,493 and a net loss of \$1,467,224. As of Dec. 31, 2006, the Company had total assets of \$1,277,690, total liabilities of \$4,462,998, and minority interest of \$187,500, resulting in a total stockholders' deficit of \$3,372,807. The Company's balance sheet as of Dec. 31, 2006, also reflected an accumulated deficit of \$8,179,419 and a negative working capital of \$4,128,608, from total current assets of \$334,390 and total current liabilities of \$4,462,998.

**Intellectual Property:** The Company entered into a licensed publisher agreement with Sony Computer Entertainment America, Inc., under which Sony granted the Company a non-exclusive license to publish, develop, market, distribute and sell software for Playstation, PlayStation 2 and handheld PSP systems in the U.S. and Canada. On September 28, 2000, it also entered into a publisher license agreement with Microsoft Corporation to develop and/or publish software products running on the Xbox game system and license proprietary materials from Microsoft. The Company also entered into a license agreement with Nintendo of America, Inc. to develop, advertise, market and sell video game software for play on the Game Boy Advance system, Nintendo GameCube system, Nintendo Wii system and Nintendo DS system. [SEC Filing 10-KSB 04-16-07]

**Description:** The Company engages in the development, publishing, and marketing of interactive entertainment software in North America and western Europe.

**Officers:** Sirius Ahmadi (CEO & Dir.); Keith Tanaka (CFO, Sec. & Dir.)

**Auditor:** Chisholm Bierwolf & Nilson LLC

**Securities:** Common Stock-Symbol CPYE.OB; OTC BB;  
51,189,065 common shares outstanding as of April 9, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0660**

**Elephant Talk Communications, Inc.**

438 East Katella Avenue, Suite 217  
Orange, CA 92867  
(714) 288-1570

NAICS	517110
Description	Telecommunications Carriers
Employees	20
Revenue (mil)	\$0.16
Income (mil)	(\$4.83)
Assets (mil)	\$13.70
Liability (mil)	\$12.83
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Kabani & Company, Inc. raised substantial doubt about the ability of Elephant Talk Communications, Inc. to continue as a going concern after auditing the Company's financial statements for the years ended December 31, 2006. The auditing firm pointed to the Company's net loss, working capital deficit, accumulated deficit, and cash used in operations. The Company posted a \$4,829,665 net loss on \$158,292 in revenues for the year ended December 31, 2006, as compared with a \$1,214,193 net loss on \$282,417 in revenues in the prior year. At December 31, 2006, the Company's balance sheet showed strained liquidity with \$4,127,723 in total current assets and \$7,309,312 in total current liabilities.

**Intellectual Property:** The Company actively pursues the protection of intellectual property rights in the United States and relevant foreign jurisdictions. The Company conducts its business under the "Elephant Talk" brand name and logo. Currently, Elephant Talk Limited owns certain trademarks in China, Singapore, Hong Kong, USA and Canada, which are either registered in the Trademark Office or in the process of being registered. [SEC Filing 10-K 04-16-07]

**Description:** The Company operates a facility-based international long distance carrier.

**Officers:** Steven van der Velden (Pres., CEO & Dir.); Willem Ackermans (CFO & Dir.); Martin Zuurbier (CTO & Dir.); Russelle Choi (Dir.); Yves van Sante (Dir.); Erik DeJonghe (Dir.); Johan DeJager (Dir.)

**Auditor:** Kabani & Company, Inc.

**Securities:** Common Stock Symbol ETLK.OB; OTCBB;  
238,265,927 common shares outstanding as of April 14, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0661**

**Favrille, Inc.**

10421 Pacific Center Court  
San Diego, CA 92121  
(858) 526-8000

NAICS	541710
Description	Biotechnology
Employees	151
Revenue (mil)	\$0.00
Income (mil)	(\$40.51)
Assets (mil)	\$72.29
Liability (mil)	\$27.65
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Favrille, Inc. reported a net loss of \$40,511,000 for the year ended December 31, 2006, higher than the net loss recorded in the past two years of \$35,875,000 in 2005 and \$26,036,000 in 2004. The Company also used cash for operating activities of \$32,105,000 in 2006, compared to \$29,609,000 in 2005 and \$20,623,000 in 2004. As a result of its recurring losses, the Company has an accumulated deficit of \$155,894,000 at December 31, 2006.

**Intellectual Property:** The Company depends on the ability to obtain and maintain patent protection for its products and technologies, preserve trade secrets and operate without infringing the intellectual property rights of others. Currently, the Company owns U.S. Patent No. 6,911,204 together with four pending United States patent applications covering methods of treating immune system diseases, including B-cell and T-cell lymphomas, using proprietary immunotherapy production methods, as well as methods for combining the idiosyncratic immunotherapies with other therapies that are used to treat diseases of the immune system. It also has 6 issued patents and over 20 patent applications pending outside of the United States. The intellectual property related to T-cell receptor-based immunotherapies includes an exclusive royalty-free license from the Sidney Kimmel Cancer Center to intellectual property developed by Dr. Daniel Gold. [SEC Filing 10-K 03-28-07]

**Description:** The Company focuses on the development and commercialization of immunotherapies for the treatment of cancer and other diseases of the immune system in the United States.

**Officers:** Michael L. Eagle (Chair); John P. Longenecker, Ph.D. (Pres., CEO & Dir.); Tamara A. Seymour (VP & CFO); Cam L. Garner (Dir.); Antonio J. Grillo-Lopez, M.D. (Dir.); Peter Barton Hutt (Dir.); David Molowa (Dir.); Fred Middleton (Dir.); Arda Minocherhomjee, Ph.D. (Dir.); Wayne I. Roe Ivor Royston, M.D. (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock-Symbol FVRL; NasdaqGM;  
32,503,721 common shares outstanding as of March 22, 2007.

[Return to top](#)



**Prospector  
Profile  
07.0662**

**GameZnFlix, Inc.**

1535 Blackjack Road  
Franklin, KY 42134  
(270) 598-0385

NAICS	516110
Description	Internet Retailer
Employees	45
Revenue (mil)	\$1.88
Income (mil)	(\$10.84)
Assets (mil)	\$6.71
Liability (mil)	\$0.86
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** GameZnFlix, Inc. reported a net loss of \$10,840,259 on revenues of \$1,884,678 for the year ended December 31, 2006, much higher than last year's net loss of \$4,239,532 on revenues of \$676,291. The Company also used cash for operating activities of \$8,494,172 in 2006, higher than last year's \$2,973,762. As a result of its recurring losses, the Company has an accumulated deficit of \$33,582,925 as of December 31, 2006.

**Intellectual Property:** In March 2004, the Company launched its website, <http://www.gameznflix.com>. The Company also developed a proprietary queue system and dynamic web server-based database system to automatically select the next title a customer receives based on factors such as the subscriber's next title preferences, title availability, length of time a subscriber has been with the Company, and the subscriber's subscription plan level. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company offers DVD movies and video games for rental and purchase through its Internet Web site [www.gameznflix.com](http://www.gameznflix.com) in the United States.

**Officers:** Donald Gallent (Pres. & Dir.); John J. Fleming (CEO, Sec. & Dir.); Arthur De Joya (CFO); Mark Crist (Dir.)

**Auditor:** Child, Van Wagoner & Bradshaw, PLLC

**Securities:** Common Stock-Symbol GZFX.OB; OTC BB; 6,058,176,376 common shares outstanding as of February 28, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0663**

**Geovax Labs, Inc.**

1256 Briarcliff Road NE  
Atlanta, GA 30306  
(404) 727-0971

NAICS	541710
Description	Biotechnology
Employees	8
Revenue (mil)	\$0.85
Income (mil)	(\$0.58)
Assets (mil)	\$2.40
Liability (mil)	\$0.19
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Tripp, Chafin & Causey, LLC raised doubts on the ability of Geovax Labs, Inc. to continue as a going concern due to its recurring losses and negative cash flows from operations.

**Intellectual Property:** The Company is the exclusive, worldwide licensee of several patents and other technologies owned by Emory University. Currently, several of these patents are approved, but not issued by the U.S. Patent and Trademark Office, with several patents pending in other countries. The Company is also the exclusive licensee of five patents from MFD, Inc. related to certain manufacturing processes. Pursuant to the MFD License Agreement, the Company obtained a fully paid, worldwide, irrevocable, exclusive license in and to the MFD Patents to use, market, offer for sale, sell, lease and import for any AIDS and smallpox vaccine made with GeoVax technology and non-exclusive rights for other products. It is also a non-exclusive licensee of four patents owned by the NIH, under which the Company licensed the patent rights and certain materials for the purpose of laboratory experiments conducted to evaluate the suitability for commercial development of the patent rights and materials. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company engages in the development and testing of human vaccines for diseases caused by human immunodeficiency virus-AIDS and other infectious agents.

**Officers:** Donald Hildebrand (Pres., CEO & Dir.); Mark Reynolds (CFO); Andrew J. Kandellapas (Dir.); Dean Kollintzas (Dir.); Robert McNally (Dir.); John N. Spencer, Jr. (Dir.)

**Auditor:** Tripp, Chafin & Causey, LLC

**Securities:** Common Stock-Symbol GOVX.OB; OTC BB;  
712,834,703 common shares outstanding as of March 23, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0664**

**Glassmaster Company, Inc.**

PO Box 788  
Lexington, SC 29071  
(803) 359-2594

NAICS	325211
Description	Plastics Mfg.
Employees	
Revenue (mil)	\$20.41
Income (mil)	(\$0.72)
Assets (mil)	\$11.60
Liability (mil)	\$11.55
(for the year ended 8/31/2006)	

**Category:** Bankruptcy

**Event:** Glassmaster Company, Inc. filed for Chapter 11 protection on April 27, 2007 with the Bankruptcy Court for the District of South Carolina, case number 07-02242, before Judge Helen E. Burris.

**Intellectual Property:** The names "Glassmaster", "CompCore", "NYBRAD", and "Glassmaster Composite Modular Building System" are registered trademarks of the Company. [SEC Filing 10-KSB 11-29-06]

**Description:** The Company is a diversified manufacturer of thermoplastic and thermoset plastic materials, industrial controls and electronics, producing and selling a broad range of product lines to customers across multiple industries.

**Officers:** Raymond M. Trehwella (CEO); Nathan G. Leaphart III (CFO); Stephen W. Trehwella (Dir.); Melvin L. Chavis (Dir.)

**Auditor:** Elliott Davis LLC

**Attorneys:** Robert Frank Anderson, Esq. of Anderson & Associates, P.A.; Columbia, SC; (803) 252-8600

**Securities:** Common Stock-Symbol GLMAE.OB; OTC BB; 2,234,390 common shares outstanding as of January 10, 2007.

**Notes:** When the Company filed for Chapter 11 protection, it listed \$10,066,068 in total assets and \$8,997,367 in total liabilities.

[Return to top](#)

**Prospector  
Profile  
07.0665**

**Guardian Technologies International, Inc.**

516 Herndon Parkway, Suite A  
Herndon, VA 20170  
(703) 464-5495

NAICS		325992
Description		Imaging Equipment Mfg.
Employees		32
Revenue	(mil)	\$0.49
Income	(mil)	(\$10.09)
Assets	(mil)	\$3.71
Liability	(mil)	\$7.13
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Goodman & Company LLP expressed substantial doubt about the ability of Guardian Technologies International, Inc. to continue as a going concern after auditing the Company's financial statements for the year ended December 31, 2006. The Company has incurred significant operating losses since inception and is dependent upon its ability to raise additional funding through debt or equity financing to continue operations. As a result, the Company may not be able to continue to meet obligations as they come due.

**Intellectual Property:** The Company relies on a combination of common law trademark, service mark, copyright and trade secret law and contractual restrictions to establish and protect proprietary rights and promote its reputation and the growth of the business. The Company has filed 2 patent applications and 11 provisional patent applications in the U.S. covering the application of its core technology. In addition, the Company expects to file 11 additional patent applications for adjunct technologies. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company engages in the design and development of imaging informatics solutions for the aviation, homeland security, and healthcare markets.

**Officers:** Michael W. Trudnak (Chair, Sec., Treas. & CEO); William J. Donovan (Pres. & COO); Gregory E. Hare (CFO); Darrell E. Hill (VP); Steven V. Lancaster (VP); Gina Marie Lindsey (Dir.); Sean W. Kennedy (Dir.); Charles T. Nash (Dir.); Michael R. Mace (Dir.)

**Auditor:** Goodman & Company LLP

**Securities:** Common Stock-Symbol GDTI.OB; OTC BB;  
34,584,849 common shares outstanding as of March 19, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0666**

**INFe-Human Resources, Inc.**

67 Wall Street, 22nd Floor  
New York, NY 10005  
(212) 859-3466

NAICS	561000
Description	Administrative & Support Services
Employees	200
Revenue (mil)	\$6.46
Income (mil)	(\$0.29)
Assets (mil)	\$3.47
Liability (mil)	\$3.22
(for the year ended 11/30/2006)	

**Category:** Loss/Deficit

**Event:** INFe Human Resources, Inc. reported a net loss of \$196,235 on revenues of \$1,644,044 for the first quarter ended Feb. 28, 2007, compared with net income of \$33,385 on revenues of \$687,932 for the same period ended Feb. 28, 2006. At Feb. 28, 2007, the Company's balance sheet showed \$3,326,308 in total assets, \$3,137,625 in total liabilities, and \$188,683 in total stockholders' equity.

**Intellectual Property:** The Company's wholly owned subsidiary INfe Human Resources - Unity, Inc. purchased Cosmo/Mazel Temps Corporation for the purpose of acquiring the rights to their current business activity and trade name. The Company valued the Cosmo/Mazel tradename at \$937,805 and the Monarch tradename at \$346,920. [SEC Filing 10-KSB 04-16-07]

**Description:** The Company, through its subsidiaries, provides human resource administrative management, executive compensation plans, and staffing services to client companies in the United States.

**Officers:** Arthur Viola (Chair, Pres. & CEO)

**Auditor:** Miller Ellin & Company LLP

**Securities:** Common Stock-Symbol IFHR.OB OTC BB;  
5,783,365 common shares outstanding as of April 11, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0667**

**Integrated Management Information, Inc.**

601 4th Street  
Platte City, MO 64079  
(816) 858-4796

NAICS		334220
Description		Transceivers Mfg.
Employees		14
Revenue	(mil)	\$1.54
Income	(mil)	(\$1.56)
Assets	(mil)	\$1.00
Liability	(mil)	\$0.70
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Gruber & Company, LLC states that conditions exist which raise substantial doubt on the ability of Integrated Management Information, Inc. to continue as a going concern unless it is able to generate sufficient cash flows to meet obligations and sustain its operations.

**Intellectual Property:** The Company has been issued a patent, No. 7,181,408, for its Livestock pricing system and has one patent pending: Serial No. 11/190, 245 for a computer program and method for establishing, documenting, implementing and maintaining a quality management system for quality systems assessment and product verification programs. The Company has been granted trademarks for the IMI logo, Passport to Profitability, Beef Passport and Grid Max. It has also filed trademark applications for Chuteside, Web Integrator, US Verified, IMI Global, Cattlenetwork and Cattlestore. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company, doing business as IMI Global, Inc., provides livestock tracking and herd management verification solutions, and consulting services to the livestock and the meat industry primarily in the United States.

**Officers:** John Saunders (Chair, Pres. & CEO); Mark D. McGregor (CFO); Leann Saunders (EVP); Dr. Gary Smith (Dir.); Adam Larson (Dir.); John Bellinger (Dir.);

**Auditor:** Gruber & Company, LLC

**Securities:** Common Stock-Symbol INMG.OB; OTC BB;  
19,328,839 common shares outstanding as of March 1, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0668**

**Interactive Motorsports and Entertainment Corp.**

5624 West 73rd Street,  
Indianapolis, IN 46278  
(317) 295-3500

NAICS 339932  
Description Video Game Mfg.

Revenue	(mil)	\$5.35
Income	(mil)	(\$0.60)
Assets	(mil)	\$1.95
Liability	(mil)	\$5.80
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** Interactive Motorsports and Entertainment Corp. reported a net loss of \$598,154 on revenues of \$5,351,298 for the year ended December 31, 2006, lower than the net loss reported last year of \$1,095,074 on revenues of \$4,838,988. The Company has stockholder's deficit of \$3,854,913 and accumulated deficit of \$9,363,302 as of December 31, 2006. The Company also has strained liquidity with \$726,018 in total current assets available to pay \$5,800,755 in total current liabilities.

**Intellectual Property:** The Company's proprietary technology includes two U.S. Patents, which combine to create what management believes to be one of the world's most realistic simulations of the sights, sounds and motions experienced by driving in an actual NASCAR race. The patented motion-based platform that the race car simulator is mounted on is among the other assets that were acquired and licensed as part of the Silicon Entertainment, Inc. asset purchase. The Company currently has two versions of race car simulators, the SMS and the Reactor, and in marketing these two products it leverages its strategic relationships and proprietary assets, which include sophisticated racing simulation technology, an exclusive licensing agreement with NASCAR, and license agreements with other racing entities including race tracks, race teams, and race sponsors to offer a unique and affordable race simulation experience. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company is in the business of manufacturing and then selling, revenue sharing or leasing race car simulators to contracted parties in malls, amusement parks, family entertainment centers, casinos and auto malls and mobile fan interactive experiences.

**Officers:** William R. Donaldson (Chair, CEO & Sec.); Carl L. Smith, Sr. (Dir.); Cary Agajanian (Dir.)

**Auditor:** HJ & Associates, LLC

**Securities:** Common Stock-Symbol IMTS.OB; OTC BB;  
96,397,506 common shares outstanding as of March 21, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0669**

**Inverness Medical Innovations, Inc.**

51 Sawyer Road, Suite 200  
Waltham, MA 02453  
(781) 647-3900

NAICS		325413
Description		Medical Devices Mfg.
Employees		2,561
Revenue	(mil)	\$569.45
Income	(mil)	(\$16.84)
Assets	(mil)	\$1,085.77
Liability	(mil)	\$371.63
(for the year ended 12/31/2006)		

**Category:** Low Rating

**Event:** Moody's Investors Service placed the Caa1, LGD5, 82% rating on Inverness Medical Innovations, Inc.'s \$150 million senior subordinated notes due 2012 on review for possible downgrade following the Company's announcement that it entered into a merger agreement with Biosite Inc. for \$90 a share for the remaining 95.3% of Biosite it does not currently own.

**Intellectual Property:** The Company has built a strong intellectual property portfolio in the area of lateral flow immunoassays, the technology which underlies many rapid diagnostic test formats including most one-step home pregnancy and fertility/ovulation tests and most of its rapid membrane products for the point-of-care marketplaces that it serves. Through acquisitions and strategic licensing, the Company has obtained rights to the major patent families in this area of technology. The Company believes that these intellectual property rights gives them a distinct advantage over competitors and underpin its continuing success in this area. In addition, its intellectual property portfolio also includes an increasing number of other patents, patent applications and licensed patents protecting its vision of the technologies and products of the future. The Company also believes that its trademarks are valuable assets that are important to the marketing of both consumer and professional products. [SEC Filing 10-K 03-01-07]

**Description:** The Company develops, manufactures and markets vitro diagnostic products for the over-the-counter pregnancy and fertility/ovulation test market, as well as the professional rapid diagnostic test market worldwide.

**Officers:** Ron Zwanziger (Chair, Pres. & CEO); Paul T. Hempel (SVP); Jerry McAleer (VP); Geoffrey Jenkins (VP); David Teitel (CFO); David Scott (Chief Scientific Officer); Carol R. Goldberg (Dir.); Robert P. Khederian (Dir.); John F. Levy (Dir.); John A. Quelch (Dir.); David Scott (Dir.); Peter Townsend (Dir.); Alfred M. Zeien (Dir.)

**Auditor:** BDO Seidman LLP

**Securities:** Common Stock Symbol IMA; AMEX;  
46,239,163 common shares outstanding as of February 26, 2007.

[Return to top](#)



**Prospector  
Profile  
07.0670**

**Lattice, Inc.**

7150 North Park Drive, Suite 500  
Pennsauken, NJ 08109  
(856) 910-1166

NAICS		334200
Description		Communications Equipment Mfg.
Employees		59
Revenue	(mil)	\$7.49
Income	(mil)	(\$16.27)
Assets	(mil)	\$13.62
Liability	(mil)	\$25.12
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Peter C. Cosmas Co. CPA's raised substantial doubt about the ability of Lattice, Inc., to continue as a going concern after auditing the Company's financial statements for the years ended December 31, 2006, and 2005. The auditing firm noted that the Company has generated significant losses and requires additional working capital to continue operations. The Company posted a \$16,271,618 net loss on a \$7,494,888 revenue for the year ended December 31, 2006, as compared with a \$863,103 net loss on a \$4,235,269 revenue in the prior year. At December 31, 2006, the Company's balance sheet showed strained liquidity with \$3,567,395 in total current assets and \$24,578,993 in total current liabilities. The Company also reported an increase in stockholder' deficit to \$11,501,098 in 2006 from \$1,277,662 in the prior year.

**Intellectual Property:** In June 1998, the Company was granted a patent (Patent No. 5,768,355) from the U.S. Patent and Trademark Office on a three-way call detection system. On December 21, 2004, the U.S. Patent and Trademark Office issued trademark serial number 78326540 for the name "Aquifer." [SEC Filing 10-KSB 04-16-07]

**Description:** The Company, formerly known as Science Dynamics Corp., provides communications products and services to corporate and government clients.

**Officers:** Paul Burgess (Pres., CEO & Dir.); Thomas R. Spadaro (VP); Joe Noto (CFO & Sec.); Eric D. Zelsdorf (CTO); Michael Ricciardi (COO); Jeannemarie Devolites Davis (Dir.); Robert E. Galbraith (Dir.); Thomas F. Gillett (Dir.); Donald Upson (Dir.)

**Auditor:** Peter C. Cosmas Co. CPA's

**Securities:** Common Stock Symbol LTTC.OB; OTCBB;  
16,629,848 common shares outstanding as of April 16, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0671**

**Lixte Biotechnology Holdings, Inc.**

248 Route 25A, No. 2  
East Setauhet, NY 11733  
(631) 942-7959

NAICS	541710
Description	Biotechnology

Revenue	(mil)	\$0.00
Income	(mil)	(\$0.49)
Assets	(mil)	\$0.75
Liability	(mil)	\$0.13

(for the year ended 12/31/2006)

**Category:** Audit Concerns

**Event:** AJ Robbins PC raised substantial doubt about Lixte Biotechnology Holdings, Inc.'s ability to continue as a going concern after auditing its financial statements. The auditing firm pointed out that the Company is in the development stage and has not commenced operations. Its ability to continue as a going concern is dependent upon its ability to develop additional sources of capital, locate and complete a merger with another company and ultimately achieve profitable operations.

**Intellectual Property:** In February 2006, a provisional patent application was filed covering methods and classes of molecules that the Company expects to be the foundation of its product development and commercialization efforts with respect to human brain tumors. In February 2007, a PCT international patent was filed containing all claims in the provisional patent plus additional claims. A non-provisional patent application with the same claims was filed in the USA. The PCT application and the non-provisional application include data supporting the original claims in the provisional patent and a number of new claims, including evidence that several drugs mentioned in the provisional patent may mimic the activity of the lead drugs named in the provisional patent, and do, in fact, have anti-tumor activity against human glioblastoma cell lines. In February 2007, a new U.S. provisional application was filed which identifies a new lead compound that has activity against glioblastoma multiform cell lines in vitro. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company develops low cost, specific, and sensitive tests for the early detection of cancers.

**Officers:** Dr. John S. Kovach (CEO & Dir.); Dr. Philip F. Palmedo (Dir.)

**Auditor:** AJ Robbins PC

**Securities:** 26,582,183 common shares outstanding as of March 15, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0672**

**Lpath, Inc.**

6335 Ferris Square, Suite A  
San Diego, CA 92121  
(858) 678-0800

NAICS		541710
Description		Biotechnology
Employees		18
Revenue	(mil)	\$0.51
Income	(mil)	(\$5.60)
Assets	(mil)	\$2.35
Liability	(mil)	\$0.80
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** LevitZacks CPAs cited several factors that raise substantial doubt about Lpath, Inc.'s ability to continue as a going concern after auditing the Company's financial statements as of Dec. 31, 2006, and 2005. The factors include the Company's significant cash losses from operations since inception and the expectation to continue to incur cash losses from operations in 2007 and beyond. For the year ended Dec. 31, 2006, the Company incurred a net loss of \$5,604,743. Accumulated deficit stood at \$13,076,057 as of Dec. 31, 2006.

**Intellectual Property:** The Company's success will depend, in part, on the ability to obtain patent protection for products in the United States and other countries. Since 1997, the Company has created a broad and deep intellectual-property position in the lysolipid signaling area. As of April 13, 2007, it owned or had exclusively licensed more than 28 issued or pending patents in the United States, with comparable coverage in major foreign countries. Seven issued or allowed patents provide ownership of anti-sphingolipid therapeutic antibodies as compositions of matter and methods to treat disease. Several patents provide claims on sphingolipids and sphingolipid receptors as targets to treat cardiovascular diseases, cancer, inflammation, angiogenesis, and various diagnostic and drug-screening applications. Lpath has other proprietary reagents and some small-molecule inhibitors that are being tested in discovery-stage studies. In 2005, Lpath purchased eight issued patents formerly assigned to Atairgin Technologies, Inc. and LPL Technologies, Inc. covering compositions of matter and methods in the cancer diagnostics and therapeutics arenas relating to related lipid-signaling pathways. [SEC Filing 10-KSB 04-16-07]

**Description:** The Company operates as a drug discovery company in the United States.

**Officers:** Scott Pancoast (Pres. & CEO); Roger Sabbadini, Ph.D. (VP & CSO); William Garland, Ph.D. (VP-Dev't); Gary Atkinson (VP & CFO); Genevieve Hansen (VP)

**Auditor:** LevitZacks CPAs

**Securities:** Common Stock-Symbol LPTN.OB; OTC BB;  
39,471,266 common shares outstanding as of April 13, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0673**

**Marshall Holdings International, Inc.**

2555 East Washburn Road  
North Las Vegas, NV 89081  
(702) 317-2400

NAICS	424210
Description	Pharmaceuticals Wholesaler
Employees	22
Revenue (mil)	\$3.76
Income (mil)	(\$3.74)
Assets (mil)	\$12.43
Liability (mil)	\$12.05
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Madsen & Associates CPA's, Inc. raised substantial doubt about the ability of Marshall Holdings International, Inc., to continue as a going concern after auditing the Company's financial statements for the year ended December 31, 2006. The auditing firm pointed to the Company's need of an additional working capital for its planned activity and to service its debt. The Company posted a \$3,735,237 net loss on a \$3,757,181 net sales for the year ended December 31, 2006. The Company's balance sheet showed strained liquidity with \$2,967,575 in total current assets and \$10,030,881 in total current liabilities.

**Intellectual Property:** Marshall has received federal trademark registration for THE RIGHT SOLUTION®. Marshall intends to continue to seek trademark protection for a number of the products and brand names under which Marshall's products are marketed. Marshall will rely upon common law concepts of confidentiality and trade secret laws to protect its product formulations. Marshall's product formulations are not protected by patents and are generally not patentable. Marshall intends to obtain international trademarks as it enters foreign markets. [SEC Filing 10-KSB 04-16-07]

**Description:** The Company, formerly known as Gateway Distributors, Ltd., operates as a distributor of vitamins, nutritional supplements, whole health foods, and skin care products.

**Officers:** Richard I .Bailey (Chair, Pres. & CEO); Florian R. Ternes (COO, Sec. & Dir.); W. Jamie Plante (CFO)

**Auditor:** Madsen & Associates CPA's, Inc.

**Securities:** Common Stock Symbol MHII.OB; OTCBB;  
2,145,357,320 common shares outstanding as of April 5, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0674**

**Migo Software Corporation**

555 Twin Dolphin Drive, Suite 650  
Redwood City, CA 94065  
(650) 232-2600

NAICS	511210
Description	Software Publisher
Employees	16
Revenue (mil)	\$0.35
Income (mil)	(\$11.47)
Assets (mil)	\$9.40
Liability (mil)	\$1.62
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** Migo Software Corporation reported a net loss of \$11,466,724 on revenues of \$345,228 for the year ended December 31, 2006, higher than the net loss reported last year of \$5,657,637 on revenues of \$194,199. The Company also used cash for operating activities of \$4,794,435 in 2006, higher than the \$3,198,717 used for operations last year. The Company has an accumulated deficit of \$44,687,065 as of December 31, 2006.

**Intellectual Property:** The Company relies primarily on a combination of copyright, trademark and patent laws, trade secrets, confidentiality procedures and contractual provisions to protect proprietary technology. For example, it seeks to avoid disclosure of trade secrets by requiring those persons with access to proprietary information to execute confidentiality agreements and by restricting access to software source code. The Company also relies on unpatented proprietary know-how in developing products, and employs various methods, including confidentiality agreements with employees, consultants and others, to protect trade secrets and know-how. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company engages in the development, acquisition, and marketing of software and infrastructure technologies designed for the storage and accession of personalized mobile information.

**Officers:** Kent Heyman (Chair & CEO); Jay Elliott (Vice Chair & Chief Strategy Officer); Richard Liebman (CFO); Robert Halligan (SVP); Greg Osborn (Dir.); Mel S. Lavitt (Dir.); Alex Mashinsky (Dir.); Malcolm Elvey (Dir.); Timothy Wallace (Dir.)

**Auditor:** Hein & Associates, LLP

**Securities:** Common Stock-Symbol MIGO.OB; OTC BB; 93,719,677 common shares outstanding as of March 12, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0675**

**Mobile Area Networks, Inc.**

2772 Depot Street  
Sanford, FL 32773  
(407) 333-2350

NAICS		333220
Description		Plastic & Rubber Products Mfg.
Employees		8
Revenue	(mil)	\$0.34
Income	(mil)	(\$0.55)
Assets	(mil)	\$0.27
Liability	(mil)	\$1.57
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Randall N. Drake, CPA, PA raised doubts on the ability of Mobile Area Networks, Inc. to continue as a going concern due to its recurring losses from operations. In addition, the Company has no commitments for funding future operations.

**Intellectual Property:** The Company owns the registered trademark mobiLAN®, and claims copyright ownership of other creative and derivative works. On April 28, 1998, the Company was granted U.S. Patent #5,745,884 which covers "System And Method For Billing Data Grade Network Use On A Per Connection Basis." [SEC Filing 10-KSB 03-29-07]

**Description:** The Company engages in the design, engineering, production of intricate plastic and rubber injection molds, as well as in the production of molded plastic and rubber parts.

**Officers:** George Wimbish (Chair, Pres., & CEO); Jerald R. Hoeft (CFO); Jerome L. Nettuno (Dir.); Noah V. Savant (Dir.)

**Auditor:** Randall N. Drake, CPA, PA

**Securities:** Common Stock-Symbol MANW.OB; OTC BB;  
46,761,080 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector  
Profile  
07.0676**

**O2Diesel Corporation**

100 Commerce Drive  
Newark, DE 19713  
(302) 266-6000

NAICS		325998
Description		Chemical Products Mfg.
Employees		17
Revenue	(mil)	\$0.25
Income	(mil)	(\$7.61)
Assets	(mil)	\$8.20
Liability	(mil)	\$1.33
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** Mayer Hoffman McCann P.C. expressed doubt about O2Diesel Corporation's ability to continue as a going concern due to its accumulated losses and lack of available working capital.

**Intellectual Property:** The Company has 109 patent applications covering eight different fuel and additive inventions relating to proprietary products registered with the international WIPO (PCT) Registration System. Four inventions currently have patents granted in a total of 32 countries in Europe, North America, Central America and Asia. An additional 12 applications relating to these inventions are pending. The other 4 inventions are either undergoing examination at the national level or are about to do so in various countries. If successful, these other 4 inventions could add up to 65 additional granted patents over the next two years. During this period, O2Diesel's intellectual property rights over its additive products are protected through its registration with the WIPO (PCT) Registration System and its pending national patent applications. The Company has filed trademark registration applications in the U.S. and the European Union for a mark which includes the words and numbers O2Diesel as well as a figurative logo of the words. The Company has also received trademark registration for "CityHome," "TODAY'S CLEAN AIR SOLUTION TOMORROW'S BRIGHTER FUTURE" and "CITYHO2ME". [SEC Filing 10-KSB 03-27-07]

**Description:** The Company offers a fuel additive product that enables distillate liquid transportation fuels to burn cleaner by facilitating the addition of ethanol as an oxygenate to these fuels.

**Officers:** Richard Roger (Pres. & COO); Alan R. Rae (CEO & Dir.); David Shipman (CFO); Hendrik Rethwilm (Dir.); Karim Jobanputra (Dir.); David L. Koontz (Dir.); E. Holt Williams (Dir.); Arthur E. Meyer (Chair); Jeffrey L. Cornish (Dir.); Gerson Santos-Leon (Dir.)

**Auditor:** Mayer Hoffman McCann P.C.

**Securities:** Common Stock-Symbol OTD; AMEX;  
76,431,001 common shares outstanding as of March 16, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0677**

**Protosource Corporation**

One Bethlehem Plaza, 4th Floor  
Bethlehem, PA 18018  
(610) 332-2893

NAICS	541511
Description	Web Design Services
Employees	141
Revenue (mil)	\$2.64
Income (mil)	(\$0.30)
Assets (mil)	\$1.05
Liability (mil)	\$7.41
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Margolis & Company P.C. states that Protosource Corporation's significant operating losses raise substantial doubt about its ability to continue as a going concern. The Company incurred net losses of \$303,697 and \$495,870 during the years ended December 31, 2006 and 2005, respectively.

**Intellectual Property:** ProtoSource's P2i Newspaper LLC subsidiary specializes in the large volume conversion of print and other content into a variety of databased, digital formats, which can then be distributed or hosted according to customer needs. Its proprietary system allows for the normalization of diverse forms of data including text and graphics, which can be integrated by a seamless, dynamic, and highly customizable front-end interface. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company, through its P2i Newspaper, Inc. subsidiary, converts the text and graphics from print media to interactive Web content.

**Officers:** Peter Wardle (Pres., CEO, CFO & Dir.); Thomas Butera (COO & Dir.); Joseph DiMarino (Dir.); Mark Blanchard (Dir.); Stewart Kalter (Dir.)

**Auditor:** Margolis & Company P.C.

**Securities:** Common Stock-Symbol PSCO.OB; OTC BB;  
9,927,329 common shares outstanding as of December 31, 2006.

[Return to top](#)



**Prospector  
Profile  
07.0678**

**Regen Biologics, Inc.**

509 Commerce Street, 1/F East Wing  
Franklin Lakes, NJ 07417  
(201) 651-5140

NAICS	339113
Description	Implants Mfg.
Employees	24
Revenue (mil)	\$0.59
Income (mil)	(\$12.66)
Assets (mil)	\$9.03
Liability (mil)	\$19.63
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Ernst & Young LLP expressed doubt on the ability of Regen Biologics, Inc. to continue as a going concern after auditing its financial statements. The auditor notes that the Company has incurred recurring net losses and has required continued infusions of external capital to fund its business.

**Intellectual Property:** The Company owns and has exclusive rights to 22 U.S. patents, 76 international patents, and 19 pending US and foreign applications. Of these patents and applications, 111 relate to the composition or application of its collagen matrix technology and 6 relate to the SharpShooter device. The Company's pending patent applications include recently filed applications directed to both the advancement of collagen matrix technology, such as membrane reinforced and lubricious coated materials, as well as a significant new device designed to fit within the SharpShooter Tissue Repair System. In addition to the patents, the Company also owns trademark registrations of the marks REGEN® and SHARPSHOOTER® and has pending trademark filings and common law rights to various other trademarks, tradenames and logos, including REGEN BIOLOGICS and CMI. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company engages in the design, development, manufacture, and marketing of human implants and medical devices for the repair and generation of soft tissue in humans.

**Officers:** Gerald E. Bisbee, Jr., Ph.D. (Chair, Pres., CEO, Sec. & Dir.); Brion D. Umidi (CFO); Abhi Acharya, Ph.D. Alan W. Baldwin Robert G. McNeil, Ph.D. William R. Timken J. Richard Steadman, M.D.

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock-Symbol RGBI.OB; OTC BB;  
103,887,843 common shares outstanding as of March 19, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0679**

**Response Biomedical Corporation**

8900 Glenlyon Parkway, Suite 100  
Burnaby, BC V5J 5J8 Canada  
(604) 456-6010

NAICS	339100
Description	Medical Equipment Mfg.
Employees	76
Revenue	CAD(mil) \$4.42
Income	CAD(mil) (\$53.59)
Assets	CAD(mil) \$12.97
Liability	CAD(mil) \$2.21
(for the year ended 12/31/2005)	

**Category:** Audit Concerns

**Event:** Ernst & Young LLP raised substantial doubt about Response Biomedical Corp.'s ability to continue as a going concern after auditing the Company's financial statements for the years ended December 31, 2006. The auditor pointed to the Company's inability to generate sufficient cash flows, significant losses to date, and dependence on series of debt and equity financings to continue its operations. The Company posted a net loss of CAD53,592,082 on revenues of CAD4,420,058 for the year ended Dec. 31, 2005, as compared with a net loss of CAD44,263,915 on revenues of CAD3,489,680 in the prior year. At Dec. 31, 2005, the Company's balance sheet showed CAD12,966,931 in total assets, CAD2,211,755 in total liabilities, and CAD10,755,176 stockholders' equity.

**Intellectual Property:** The Company relies on a combination of patents, trademarks, confidential procedures, contractual provisions and similar measures to protect proprietary information. To develop and maintain its competitive position, the Company also relies upon continuing invention, trade secrets and technical know-how, and require employees to enter into non-disclosure and non-competition agreements to protect proprietary information that is not patented. To date, the Company has six patents registered with the U.S. Patent and Trademark Office and 12 related patents registered worldwide. It has registered "RAMP" and the "R" logo and design in Canada, the United States, and the European Union. "RAMP" has also been registered in China and it has filed for registration in Japan. [SEC Filing 20-F 06-30-06]

**Description:** The Company develops, manufactures and markets rapid on-site RAMP tests for medical and environmental applications providing reliable information.

**Officers:** Richard J. Bastiani (Chair); William J. Radvak (Pres., CEO & Dir.); Brian G. Richards (COO, Sec. & Dir.); Robert G. Pilz (VP & CFO); Paul C. Harris (VP); Reed W. Simmons (VP); Joanne M. Stephenson (VP); Anthony F. Holler (Dir.); Todd R. Patrick (Dir.); Ian A. Webb (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock Symbol RBM.V; TSX-V;  
67,700,472 common shares outstanding as of December 31, 2005.

[Return to top](#)

**Prospector  
Profile  
07.0680**

**Security with Advanced Technology, Inc.**

10855 Dover Street, Suite 1000  
Westminster, CO 80021  
(303) 439-0372

NAICS		334310
Description		Video Equipment Manufacturing
Employees		38
Revenue	(mil)	\$0.30
Income	(mil)	(\$9.35)
Assets	(mil)	\$8.93
Liability	(mil)	\$1.28
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** GHP Horwath, P.C. raise substantial doubt about the ability of Security With Advanced Technology, Inc. to continue as a going concern after auditing the Company's financial statements for the year ended Dec. 31, 2006. The auditing firm pointed to the Company's inability to generate significant revenues in 2006, net loss of about \$9,347,000, and consumed cash in operating activities of about \$5,651,000, for the year ended Dec. 31, 2006.

**Intellectual Property:** The Company's Avurt product line currently has three pending patent applications with claims covering the launcher concept, the Avurt IM-5 housing, and the Avurt IM-5 mechanics. Its Veritas Tactical product line currently has one filed patent application for SafeMunitions covering the product concept and several patents in process covering multiple weapon conversions and conversion concepts. In addition to the SafeMunitions product line, the non-lethal line of tactical products has three patents in process dealing with the magazine fed tactical launchers and new features tied to that line of products. The Company's Vizer Group subsidiary has one filed patent on the web hosted access control and security software relating to the concept and the specifics of the software solution. Its ShiftWatch® product line currently has pending patent applications with claims covering over 30 features of the product, including the base Tapestream™ technology. [SEC Filing 10-KSB 04-17-07]

**Description:** The Company provides security products and services, which include non-lethal personal protection devices, surveillance and intrusion detection systems and mobile digital video surveillance solutions.

**Officers:** Gregory Pusey (Chair); Scott Sutton (Pres., CEO & Dir.); Jeffrey G. McGonegal (CFO); Gail Schoettler (Dir.); Robert J. Williams (Dir.); David Welch (Dir.); Thomas R. Marinelli (Dir.)

**Auditor:** GHP Horwath, P.C.

**Securities:** Common Stock-Symbol SWATW; Nasdaq;  
4,872,467 common shares outstanding as of April 12, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0681**

**SinoFresh Healthcare, Inc.**

516 Paul Morris Drive  
Englewood, FL 34223  
(941) 681-3100

NAICS	541710
Description	Biotechnology
Employees	6
Revenue (mil)	\$1.08
Income (mil)	(\$4.96)
Assets (mil)	\$2.35
Liability (mil)	\$4.55
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Moore Stephens Lovelace, P.A. raised substantial doubt about SinoFresh HealthCare, Inc.'s ability to continue as a going concern after auditing the Company's financial statements as of Dec. 31, 2006. The auditing firm reported that the Company is in default on its debenture obligations, has incurred substantial losses since its inception, has a working capital deficiency at Dec. 31, 2006, and has incurred negative cash flow from operations. Net loss for the year 2006 was \$4,963,031 on revenues of \$1,083,576. As of Dec. 31, 2006, the company had a negative working capital of \$4,303,356 and accumulated deficit of \$14,783,996.

**Intellectual Property:** The Company currently owns three U.S. patents under which it has the exclusive right to manufacture, market and distribute in the U.S. a proprietary composition for freshening the nostrils and sinus cavities. All three patents were issued to Charles Fust, the principal of SinoFresh Laboratories, Inc., who subsequently assigned them to the Company. In July, 2005, a utility patent filing, Serial Number 11/187,575 was submitted entitled, Methods And Compositions For Inhibiting, Destroying, And/or, Inactivating Viruses. The Company has patents or patent applications pending for the Company's proprietary composition in Canada and various other foreign countries in Europe, Eastern Europe, Asia, Latin America and the Middle East. The Company currently has trademark rights and/or trademark registrations on the "SINO-FRESH" and "SinoFresh" names in the United States and several foreign countries. [SEC Filing 10-KSB 04-16-07]

**Description:** The Company engages in the research, development, and marketing of novel therapies to treat inflammatory and infectious diseases, and disorders of the upper respiratory system.

**Officers:** Charles A. Fust (Chair, CEO & Dir.); Scott M. Klein (CFO & Sec.); Stacey Maloney-Fust (SVP, Sec. & Dir.); P. Robert DuPont (Dir.); Stephen Bannon (Dir.); David Otto (Dir.)

**Auditor:** Moore Stephens Lovelace, P.A.

**Securities:** Common Stock-Symbol SFSH.OB; OTC BB; 16,902,055 common shares outstanding as of March 20, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0682**

**Solomon Technologies, Inc.**

1400 L&R Industrial Boulevard  
Tarpon Springs, FL 34689  
727-934-8778

NAICS		333618
Description		Electric Motors Manufacturing
Employees		51
Revenue	(mil)	\$2.28
Income	(mil)	(\$16.26)
Assets	(mil)	\$7.79
Liability	(mil)	\$6.92
(for the year ended 12/31/2006)		

**Category:** Loss/Deficit

**Event:** Solomon Technologies, Inc. posted a net loss of \$2,911,083 on net sales of \$823,531 for the third quarter ended Sept. 30, 2006, compared with a net loss of \$1,544,163 on net sales of \$3,674 for the same period last year. At Sept. 30, 2006, the Company's balance sheet showed \$11,564,716 in total assets, \$6,135,070 in total liabilities, and \$5,429,646 in total stockholders' equity. The Company's balance sheet at Sept. 30, 2006, also showed strained liquidity with \$3,059,012 in total current assets available to pay \$6,135,070 in total current liabilities.

**Intellectual Property:** The Company has filed for registration of the terms Electric Wheel and Electric Transaxle and has registered the name "Solomon Technologies" and logo with the U.S. Patent and Trademark Office under three trademark filings. In 1999, the Company trademarked a stylized version of the phrase "Electric Wheel" in the U.S. in connection with electric propulsion systems. The Company currently has 14 patents in the U.S. and foreign jurisdictions relating to its electric wheel technology and Electric Transaxle technology. The Company also has 8 patents pending for its regenerative motor propulsion systems; system for automation for power generation, propulsion and use management; and system and apparatus for a multiple input and dual output electric differential motor device utilizing one ring gear. [SEC Filing 10-KSB 04-02-07]

**Description:** The Company engages in the development, engineering, manufacture, license, and sale of electric power drive systems.

**Officers:** Gary M. Laskowski (Chair & VP); Peter W. DeVecchis, Jr. (Pres.); Gary G. Brandt (CEO); Samuel F. Occhipinti (CFO); Michael D'Amelio (VP & Dir.); Jonathan D. Betts (Dir.); Duane L. Crisco (Dir.); David J. Parcels (Dir.)

**Auditor:** UHY LLP

**Securities:** Common Stock-Symbol SOLM.OB OTC BB;  
36,055,693 common shares outstanding as of March 27, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0683**

**Sontra Medical Corporation**

10 Forge Parkway  
Franklin, MA 02038  
(508) 553-8850

NAICS	541710
Description	Biotechnology
Employees	5
Revenue (mil)	\$0.09
Income (mil)	(\$5.35)
Assets (mil)	\$0.81
Liability (mil)	\$0.34
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Wolf & Company PC expressed doubt about Sontra Medical Corporation's ability to continue as a going concern after auditing its financial statements. The auditor noted that the Company has suffered recurring losses from operations, has a significant accumulated deficit and has been unable to raise sufficient capital to fund its operations.

**Intellectual Property:** Sontra owns or exclusively licenses patents and patent applications that are very broad in scope, including ultrasound-enhanced transdermal drug delivery and ultrasound-enhanced transdermal enabled analyte extraction and measurement. Sontra has also patented specific elements of the technology that are keys to successful skin permeation with a precise feedback control. Sontra has not sought patent protection for all of its technology but focuses its patent coverage only on aspects of its technologies that will be significant and that could provide barriers to entry for its competition worldwide. The Company has an exclusive license from MIT to 8 issued patents in the United States, 4 issued foreign patents, 1 pending U.S. patent and 1 pending foreign patent application. As of December 31, 2006, the Company owned 6 issued patents and 11 pending patent applications in the U.S. and 4 issued foreign patents and 26 pending foreign applications. Sontra intends to file patent applications covering newly developed products and technologies. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company engages in the development of transdermal diagnostic and drug delivery products based on its SonoPrep ultrasonic skin permeation technology.

**Officers:** Michael R. Wigley, M.B.A. (Chair); Harry G. Mitchell (Interim CEO, CFO & Treas.); Walter W. Witoshkin (Dir.); Robert S. Langer, Sc.D. (Dir.); Joseph F. Amaral, M.D. (Dir.); Gerard E. Puorro (Dir.); Brian Sullivan (Dir.)

**Auditor:** Wolf & Company PC

**Securities:** Common Stock-Symbol SONT; NasdaqCM;  
9,386,679 common shares outstanding as of March 23, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0684**

**Spatializer Audio Laboratories, Inc.**

2060 East Avenida De Los Arboles  
Thousand Oaks, CA 91362  
(408) 453-4180

NAICS	334310
Description	Audio Equipment Mfg.
Employees	2
Revenue (mil)	\$0.33
Income (mil)	(\$0.35)
Assets (mil)	\$0.46
Liability (mil)	\$0.09
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** After auditing Spatializer Audio Laboratories, Inc.'s financial statements for the year ended December 31, 2006, Ramirez International Financial & Accounting Services, Inc. expressed doubt on the Company's financial statements due to its significant operating losses.

**Intellectual Property:** The Company relies on a variety of intellectual property protections for products and services, including patent, copyright, trademark and trade secret laws, and contractual obligations. On March 20, 1998, the Company filed a patent application on its enCompass V 2.0 technology with the United States Patent & Trademark Office covering the enCompass 2.0 positional audio gaming technology. In June 2000, the Company filed an additional patent application for its reduced cost/higher performance 3-D Stereo circuit design. In late 2002, the Company filed a patent application covering its Spatializer PCE technology. In 2003, it filed a patent application for Spatializer Audio Alchemy. Much of the Company's intellectual property consists of trade secrets. It also has copyright protection for its principal software applications and has U.S. and foreign trademark protection for its key product names and logo marks. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company, through its subsidiaries, engages in the development, licensing, and marketing of audio signal processing technologies for the consumer electronics, personal computing, entertainment, and cellular telephone markets.

**Officers:** Harry R. Mandell (Chair); Carlo Civelli (Dir.)

**Auditor:** Ramirez International Financial & Accounting Services, Inc.

**Securities:** Common Stock-Symbol SPAZ.OB; OTC BB;  
48,763,383 common shares outstanding as of February 25, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0685**

**Spectrascience, Inc.**

11568 Sorrento Valley Road, Suite 11  
San Diego, CA 92121  
(858) 847-0200

NAICS		339100
Description		Medical Equipment Mfg.
Employees		3
Revenue	(mil)	\$0.00
Income	(mil)	(\$1.31)
Assets	(mil)	\$0.59
Liability	(mil)	\$0.07
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** J.H. Cohn LLP expressed substantial doubt about the ability of Spectrascience, Inc. to continue as a going concern. The auditor noted that the Company has incurred losses and negative cash flows from operating activities from its inception. As of December 31, 2006, management believes that the Company will require additional financing to fund its operations, but cannot assure that such financing will be available.

**Intellectual Property:** SpectraScience currently owns exclusive rights to a total of eight issued US patents and international patents. SpectraScience has eight issued US patents and is the exclusive licensee through the Massachusetts General Hospital of US Patent 5,843,000 and a pending international patent application. Three of the issued patents and pending patent applications are focused on types of forceps having an optical fiber and biopsy jaws which are positioned to take samples for biopsy or to remove tissue as therapy from the precise area of view of the optical fiber, and methods of tissue diagnosis using these forceps. One issued patent pertains to the WavSTAT™ System and methods of use. The remaining US patents pertain to various apparatus and methods of diagnosing tissue, and providing the physician with additional information regarding whether it is necessary to take a biopsy sample. In October 2006, the Company filed for a patent entitled “System and Method for Non-Endoscopic Optical Biopsy Detection of Diseased Tissue”. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company engages in the development and manufacture of medical devices in the United States.

**Officers:** Jim Hitchin (Chair, Pres., CEO, CFO & Corp. Sec.); Mark D. McWilliams (Dir.); Rand P. Mulford (Dir.); Chester E. Sievert, Jr. (Dir.); Stanley J. Pappelbaum (Dir.)

**Auditor:** J.H. Cohn LLP

**Securities:** Common Stock-Symbol SCIE.OB; OTC BB;  
38,370,087 common shares outstanding as of March 23, 2007.

[Return to top](#)



**Prospector  
Profile  
07.0686**

**Surflect Holdings, Inc.**

12000-G Candelaria NE  
Albuquerque, NM 87112  
(505) 294-6354

NAICS		332813
Description		Electroplating Services
Employees		12
Revenue	(mil)	\$0.22
Income	(mil)	(\$2.95)
Assets	(mil)	\$2.85
Liability	(mil)	\$0.59
(for the year ended 12/31/2006)		

**Category:** Audit Concerns

**Event:** REDW LLC raised doubts on Surflect Holdings, Inc.'s ability to continue as a going concern after auditing its financial statements. The Company has incurred net losses since its inception and net losses has continued to date. Surflect remains dependent on its ability to raise adequate capital to fund necessary market entry activities.

**Intellectual Property:** The Company has sought U.S. and international patent protection of key technologies used in its business. As of December 31, 2006, the Company has three registered patents and six pending patent applications with the U.S. Patent and Trademark Office. To protect trade secrets, the Company plans to provide certain of its controlled process intellectual property as part of a tool transaction while continuing to develop additional process applications to exploit the tool intellectual property. The Company has registered the domain name www.surflect.com, as well as acquired trademark registration for Surflect®. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company, through its wholly owned subsidiary, Surflect Technologies, Inc., operates as a design and manufacturing company in the United States.

**Officers:** Steven Anderson (Pres., CEO, Sec., Treas. & Dir.); James Turk (CFO); Yixiang Xie (Chief Technology Officer); Miles A. Prim (COO); Mark W. Eichhorn (VP); Laurence P. Wagner (Dir.); Chad Brownstein (Dir.); Jonah Schnel (Dir.)

**Auditor:** REDW LLC

**Securities:** Common Stock-Symbol SUFH.OB; OTC BB;  
14,201,667 common shares outstanding as of March 28, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0687**

**Targeted Genetics Corporation**

1100 Olive Way, Suite 100  
Seattle, WA 98101  
(206) 623-7612

NAICS	541710
Description	Biotechnology
Employees	70
Revenue (mil)	\$9.86
Income (mil)	(\$33.99)
Assets (mil)	\$17.47
Liability (mil)	\$12.10
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Ernst & Young LLP raised substantial doubt about the ability of Targeted Genetics Corporation to continue as a going concern due to its recurring losses, negative cash flows from operations and limited working capital.

**Intellectual Property:** The Company has licensed technology underlying several issued and pending patents, including two licenses to patents for the manufacture of AAV vectors and the use of AAV vectors for gene delivery. The exclusive license with Alkermes, Inc. provides the Company with rights to patents broadly covering a manufacturing method that is critical to making AAV-based products in a commercially viable, cost-effective manner. This technology, developed by Children's Hospital in Columbus, Ohio, covers the use of cell lines for manufacturing AAV vectors in multiple disease areas. Its license with the University of Pennsylvania provides the Company with exclusive and non-exclusive licenses to a group of patents and patent applications with claims that cover AAV and adenoviral vector technologies including manufacturing methods. In addition, the license provides them with exclusive rights to components of a specific serotype of AAV called AAV1. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company engages in the research and development of gene therapy products and technologies for the treatment of acquired and inherited diseases.

**Officers:** Jeremy Curnock Cook (Chair); H. Stewart Parker (Pres., CEO & Dir.); Barrie J. Carter, Ph.D. (EVP & Chief Scientific Officer); David Poston (VP, Treas. & CFO); Pervin Anklesaria, Ph.D. (VP); B.G. Susan Richardson (VP); Richard W. Peluso, Ph.D. (VP); Jack L. Bowman (Dir.); Roger L. Hawley (Dir.); Joseph M. Davie, M.D., Ph.D. (Dir.); Nelson L. Levy, Ph.D., M.D. (Dir.); Michael Perry, D.V.M., Ph.D. (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock-Symbol TGEN; NasdaqCM;  
13,108,735 common shares outstanding as of March 16, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0688**

**Teeka Tan Products, Inc.**

5499 North Federal Highway, Suite D  
Boca Raton, FL 33487  
(561) 989-3600

NAICS	325620
Description	Tanning Lotions Mfg.
Employees	2
Revenue (mil)	\$0.25
Income (mil)	(\$0.65)
Assets (mil)	\$0.19
Liability (mil)	\$0.62
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Webb & Company PA expressed doubts on the ability of Teeka Tan Products, Inc. to continue as a going concern. The auditing firm pointed out that the Company has a net loss of \$645,702 and used cash in operations of \$254,429 for the year ended December 31, 2006. It also has a working capital deficiency of \$457,765 and a stockholders' deficiency of \$431,416 at December 31, 2006.

**Intellectual Property:** The Company has secured federal registration of its TeekaTan trademark and also obtained the right to the Internet address www.teekatan.com. The Company's Safe Sea product line contains a patented mix of chemicals that mimics the protective coating of the clown fish. In May 2006, the Company engaged Shark Defense in connection with the development of a sunscreen product containing a shark repellent. Following the conclusion of the first phase of the research project, the Company hired Shark Defense to assist in the preparation and filing of a provisional patent application for the formula, as well as experimental design and technical support. [SEC Filing 10-KSB 03-28-07]

**Description:** The Company, through its wholly owned subsidiary, Teeka Tan, Inc., markets and distributes sun care products in the United States and internationally.

**Officers:** Brian S. John (Pres., CEO & Dir.); Richard A. Miller (VP, COO & Dir.); Frank J. Benedetto, Jr. (Treas., Corp. Sec. & Dir.)

**Auditor:** Webb & Company PA

**Securities:** Common Stock-Symbol TKAT.OB; OTC BB;  
88,206,665 common shares outstanding as of March 20, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0689**

**Telanetix, Inc.**

6197 Cornerstone Court E, Suite 108  
San Diego, CA 92121  
(858) 362-2250

NAICS	561499
Description	Videoconferencing
Employees	9
Revenue (mil)	\$1.31
Income (mil)	(\$3.12)
Assets (mil)	\$4.28
Liability (mil)	\$5.77
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Burnham & Schumm, P.C. states that several factors create an uncertainty as to Telanetix, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditor notes that the Company has incurred a net loss of \$3,119,056 and \$2,139,423 during the years ended December 31, 2006 and 2005, respectively and accumulated losses of \$10,013,433 since opening for business.

**Intellectual Property:** The Company markets its videoconferencing solutions under the trademark Digital Presence™. [SEC Filing 10-KSB 03-29-07]

**Description:** The Company engages in the development and marketing of video conferencing solutions primarily the United States.

**Officers:** Thomas A. Szabo (Chair & CEO); Richard M. Ono (CFO)

**Auditor:** Burnham & Schumm, P.C.

**Securities:** Common Stock-Symbol TNXI.OB; OTC BB;  
15,634,251 common shares outstanding as of March 19, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0690**

**TorreyPines Therapeutics, Inc.**

11085 North Torrey Pines Road, Suite 300  
La Jolla, CA 92037  
(858) 623-5665

NAICS	541710
Description	Biotechnology
Employees	43
Revenue (mil)	\$9.85
Income (mil)	(\$25.38)
Assets (mil)	\$63.43
Liability (mil)	\$18.86
(for the year ended 12/31/2006)	

**Category:** Loss/Deficit

**Event:** TorreyPines Therapeutics, Inc. reported a net loss of \$25,376,947 for the year ended December 31, 2006, higher than the net loss reported of \$11,542,004 in 2005 and \$10,355,905 in 2004. The Company also reported increased revenues of \$9,850,000 in 2006, higher than the revenues of \$7,966,667 in 2005 and \$3,551,025 in 2004. As a result of recurring losses, the Company has accumulated deficit of \$73,032,007 as of December 31, 2006.

**Intellectual Property:** As of December 31, 2006, the Company controlled approximately 317 patents and patent applications worldwide. Of these, 55 pertain to tezampanel and/or NGX426 (including 12 issued U.S. patents), 51 pertain to NGX267 and/or NGX292 (including 3 issued U.S. patents), 87 pertain to phenserine and/or Posiphen (including 3 issued U.S. patents), 40 pertain to BNC (including 2 issued U.S. patents), and 14 pertain to NGX555 (including 1 allowed U.S. patent application). Issued patents, and patents that may issue from these pending applications, would expire between 2010 and 2025. The Company owns the TORREYPINES THERAPEUTICS and Design trademark, which is registered in the U.S. and in Japan, Canada, and the European Community. It also owns the Tree Logo trademark, which is registered in the U.S. Additionally, the Company owns the POSIPHEN trademark, which is registered or pending in approximately 25 countries. [SEC Filing 10-K 03-29-07]

**Description:** The Company engages in the discovery, development, and commercialization of small molecules to treat diseases and disorders of the central nervous system.

**Officers:** Neil M. Kurtz, M.D. (Pres., CEO & Dir.); Craig Johnson (VP & CFO); William T. Comer, Ph.D. (Dir.); Peter Davis, Ph.D. (Dir.); Jean Deleage, Ph.D. (Dir.); Steven H. Ferris, Ph.D. (Dir.); Jason Fisherman, M.D. (Dir.); Steven Ratoff (Dir.); Patrick Van Beneden (Dir.); Louis G. Cornacchia (Dir.); Marvin S. Hausman, M.D. (Dir.)

**Auditor:** Ernst & Young LLP

**Securities:** Common Stock-Symbol TPTX; Nasdaq;  
15,700,039 common shares outstanding as of March 15, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0691**

**Tribeworks, Inc.**

2001 152nd Avenue North East  
Redmond, WA 98052  
(425) 458-2360

NAICS	541511
Description	Software Services
Employees	28
Revenue (mil)	\$0.04
Income (mil)	(\$1.82)
Assets (mil)	\$1.67
Liability (mil)	\$0.90
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Williams & Webster, P.S. reported that Tribeworks, Inc.'s significant operating losses raise substantial doubt about its ability to continue as a going concern after auditing the Company's financial statements as of Dec. 31, 2006, and 2005. For the year 2006, the Company listed revenues of \$39,706 and a net loss of \$1,818,551. The Company's December 31 balance sheet also showed strained liquidity with total current assets of \$205,656 available to pay total current liabilities of \$899,992.

**Intellectual Property:** The Company relies on a combination of copyright laws, trademark laws, contract laws, and other intellectual property protection methods to protect its technology, names and logos in the United States and other countries. Tribeworks' patented and trademarked "iShell" product and logo, which until mid 2006 was its lead product, were sold during 2006 to a former staff member. On January 20, 2006, the Company acquired AtlasTG, which resulted in additional proprietary rights such as AtlasTG's unique OnBoarding processes as well as a range of trade secrets relating to its IT support technologies. The Company is now in the process of applying for a number of patents and trademarks for these systems, processes and their unique names as part of securing proprietary products and establishing its marketing and branding. [SEC Filing 10-KSB 04-16-07]

**Description:** The Company, through its principal subsidiary, Atlas Technology Group, provides outsourced application software support services for clients with large information technology functions worldwide.

**Officers:** Peter B. Jacobson (CEO & Dir.); B.S.P. Marra (CFO & Dir.); Michael T. Murphy (COO); Robert E Altinger (Dir.); Andrew J.E. Berger (Dir.); W. Gordon Blankstein (Dir.); Robert C. Gardner (Dir.)

**Auditor:** Williams & Webster, P.S.

**Securities:** Common Stock-Symbol TWKS.OB; OTC BB; 26,331,805 common shares outstanding as of April 11, 2007.

[Return to top](#)

**Prospector  
Profile  
07.0692**

**Visiphor Corporation**

Suite 1100 – 4710 Kingsway  
Burnaby, British Columbia V5H 4M2  
Canada  
(604) 684-2449

NAICS	541511
Description	Computer Programming Services
Employees	55
Revenue (mil)	\$6.38
Income (mil)	(\$6.68)
Assets (mil)	\$3.92
Liability (mil)	\$4.51
(for the year ended 12/31/2006)	

**Category:** Audit Concerns

**Event:** Grant Thornton LLP expressed doubts on the ability of Visiphor Corporation to continue as a going concern after auditing its financial statements. For the year ended December 31, 2006, the Company incurred a loss from operations of \$6,678,371 and a deficiency in operating cash flow of \$2,602,248. In addition, the Company has incurred significant operating losses and net utilization of cash in operations in all prior periods. Accordingly, the Company will require continued financial support from its shareholders and creditors until it is able to generate sufficient cash flow from operations on a sustained basis.

**Intellectual Property:** The Company relies on a combination of copyright, patent and trade secret laws, non-disclosure agreements and other contractual provisions to establish and maintain its proprietary rights. As part of its confidentiality procedures, the Company generally enters into nondisclosure and confidentiality agreements with key employees, consultants, and business partners and limits access to and distribution of its technology, documentation, and other proprietary information. In addition, the Company's source code for its software products is maintained in a controlled environment within the technology and development group. [SEC Filing 10-KSB 03-26-07]

**Description:** The Company provides software products and consulting services and specializes in the development and deployment of solutions to the problem of integrating disparate business processes and databases.

**Officers:** Oliver Revell (Chair); Roy Trivett (CEO & Dir.); Sunil Amin (CFO); Al Kassam (VP); Clyde Farnsworth (Dir.); Keith Kretschmer (Dir.); Michael C. Volker (Dir.); Norman Inkster (Dir.); Wanda Dorosz (Dir.)

**Auditor:** Grant Thornton LLP

**Securities:** Common Stock-Symbol VIS.V; CDNX;  
44,114,775 common shares outstanding as of March 22, 2007.

[Return to top](#)